Lilly says weight loss drug cuts heart failure risk by 38% in trial – Reuters

Lilly says weight loss drug cuts heart failure risk by 38% in trial  ReutersLilly’s tirzepatide successful in phase 3 study showing benefit in adults with heart failure with preserved ejection fraction and obesity  Investors | Eli Lilly and CompanyEli Lilly’s tirzepatide cuts heart failure risks, company says  NBC NewsEli Lilly Finds Yet Another Condition for Zepbound to Treat. The Stock Is Up.  Barron’sEli Lilly, after tirzepatide’s late-stage cardio win, plots regulatory filings this year  FiercePharma